Discontinued — last reported Q4 '22
Complex Gx and Biosimilars — Finite-lived intangible assets, net
Viatris Complex Gx and Biosimilars — Finite-lived intangible assets, net decreased by 21.9% to $178.40M in Q4 2022 compared to the prior quarter.
Analysis
How to read this metric
An increase suggests recent acquisitions or investments in new product pipelines, while a decrease indicates ongoing amortization or potential impairment of existing assets. High levels relative to revenue may signal significant future amortization expenses that could impact long-term profitability.
Detailed definition
This metric represents the net book value of finite-lived intangible assets specifically attributable to the complex gen...
Peer comparison
Comparable to 'Intangible Assets, Net' or 'Product Rights' reported by other pharmaceutical companies focused on generic and specialty drug portfolios.
vtrs_segment_complex_gx_and_biosimilars_finite_lived_intangible_assets_netHistorical Data
| Q4 '21 | Q4 '22 | |
|---|---|---|
| Value | $228.30M | $178.40M |
| QoQ Change | — | -21.9% |
| YoY Change | — | -21.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's complex gx and biosimilars — finite-lived intangible assets, net?
- Viatris (VTRS) reported complex gx and biosimilars — finite-lived intangible assets, net of $178.40M in Q4 2022.
- What does complex gx and biosimilars — finite-lived intangible assets, net mean?
- The net accounting value of intellectual property and product rights for complex generic and biosimilar drugs that will expire over a set period.